Skip to main content

Table 3 Costs after COVID-19 based on health insurance claims data from 2021 (mean ± SD in €)

From: COVID-19-associated costs and mortality in Germany: an incidence-based analysis from a payer’s perspective

 

CG 1

IG 1

CG 2

IG 2

CG 3

IG 3

Total healthcare costs

  ≤ 19

 20–39

 40–59

  ≥ 60

3123 ± 8475a

1351 ± 3319a

2310 ± 6998a

3243 ± 9432a

5725 ± 10491a

4211 ± 11532a, c

1940 ± 7624a, c

2587 ± 9594a, c

4778 ± 13166a, c

7763 ± 11999a, c

3449 ± 8219a

1862 ± 4679a

2482 ± 6389a

3400 ± 7031a

6753 ± 14208a

6153 ± 10596a, b, c

1557 ± 1228a, b

3598 ± 5570a, b, c

6747 ± 11918a, b, c

9194 ± 11160a, b, c

3072 ± 8513a

1297 ± 3143a, c

2280 ± 7099a

3216 ± 9789a

5591 ± 9911a

3911 ± 11642a, b, c

1961 ± 7826a, c

2478 ± 9925a, c

4319 ± 13403a, c

7560 ± 12109a, c

Hospital costs

  ≤ 19

 20–39

 40–59

 ≥ 60

907 ± 4358a

310 ± 1988c

779 ± 4569

812 ± 4097a

1878 ± 5786a

1494 ± 7072a, c

356 ± 2244

681 ± 3705

1673 ± 9050a, c

3560 ± 8071a, c

947 ± 4316a

698 ± 3878

804 ± 4469a

766 ± 3510a

1994 ± 6165a

2385 ± 7386a, b, c

382 ± 878b

1244 ± 3848a, b, c

2568 ± 8529a, b, c

4074 ± 7248a, c

901 ± 4366a

269 ± 1671

775 ± 4588

820 ± 4191a

1863 ± 5740a

1356 ± 7014a, b, c

354 ± 2296

620 ± 3686

1464 ± 9157a, c

3487 ± 8185a, c

Costs of outpatient med. care

  ≤ 19

 20–39

 40–59

  ≥ 60

627 ± 893a

397 ± 726a

519 ± 771a

655 ± 907a

938 ± 1073a

757 ± 913a, c

506 ± 670a, c

601 ± 721a, c

808 ± 952a, c

1135 ± 1150a, c

710 ± 1017a

410 ± 456a

596 ± 844a

739 ± 1098a

1075 ± 1250a

1074 ± 1057a, b, c

641 ± 454a, b, c

876 ± 730a, b, c

1100 ± 968a, b, c

1420 ± 1699a, b, c

614 ± 872a

395 ± 749a, c

506 ± 758a

640 ± 870a

920 ± 1048a

708 ± 878a, b, c

499 ± 679a, c

572 ± 714a, c

740 ± 935a, c

1095 ± 1046a

Drug costs

  ≤ 19

 20–39

 40–59

  ≥ 60

491 ± 2460a

111 ± 803a, c

234 ± 1468

559 ± 2485a

1080 ± 4045

717 ± 5082a, c

412 ± 5001a

610 ± 6530c

749 ± 4420a, c

1103 ± 3367

555 ± 2905a

84 ± 215a

172 ± 757a

610 ± 2768a

1515 ± 5680

480 ± 1519a, b, c

129 ± 209a, b

286 ± 1289a, b, c

483 ± 1589a, b, c

886 ± 1731

481 ± 2384a

114 ± 842a, c

245 ± 1557

551 ± 2433a

1023 ± 3782

754 ± 5427a, b

427 ± 5136a

645 ± 6857

811 ± 4847a, c

1133 ± 3538

Costs of sick pay

  ≤ 19

 20–39

 40–59

  ≥ 60

297 ± 1847a

1 ± 30

269 ± 1825a

379 ± 1852a

402 ± 2532

397 ± 2200a, c

2 ± 47

204 ± 1523a, c

703 ± 2943a, c

278 ± 1730

432 ± 2207a

0 ± 0

388 ± 2102a

537 ± 2127a

506 ± 3236

1276 ± 3888a, b, c

39 ± 205b

604 ± 2247a, b, c

1756 ± 4644a, b, c

729 ± 2549b

276 ± 1784

1 ± 32

248 ± 1774

351 ± 1780

388 ± 2428

262 ± 1767b, c

0 ± 6

161 ± 1419c

457 ± 2311c

214 ± 1573

Other healthcare costs

  ≤ 19

 20–39

 40–59

  ≥ 60

801 ± 4341a, c

531 ± 1532

508 ± 1424

838 ± 6057c

1428 ± 4015a

846 ± 3172a, c

664 ± 4542

491 ± 1968

846 ± 3222c

1687 ± 3303a

805 ± 2503a

670 ± 1292

521 ± 1377

749 ± 1740a

1664 ± 5325a

938 ± 2073a, b, c

367 ± 401

587 ± 1198b, c

840 ± 1354a, b, c

2085 ± 4359a

800 ± 4559c

517 ± 1556

506 ± 1433

854 ± 6520c

1397 ± 3816a

831 ± 3309b

680 ± 4664

480 ± 2034

847 ± 3518c

1631 ± 3126a

  1. Abbreviations: CG 1–3 Control group to IG 1–3, IG 1 Investigation group in total, IG 2 Investigation group including Post-COVID-19 Syndrome (PCS) patients only, IG 3 Investigation group excluding PCS patients, n sample size, SD Standard deviation
  2. aSignificant difference (p < 0.05) between IG and respective CG (Mann–Whitney U test)
  3. bSignificant difference (p < 0.05) between IG 2 and IG 3 (Mann–Whitney U test)
  4. cSignificant difference (p < 0.05) between 2020 and 2021 (Wilcoxon signed-rank test)